The announcement last week that Bristol-Myers Squibb will acquire drugmaker Celgene in a $74-billion deal is a big bet on a line-up of cancer drugs as 2019 ushers in a push to raise the price of over 1,000 medications and earns the industry a great deal of scrutiny in Washington.
Shares of Celgene spiked on the news Thursday, while Bristol’s flopped…. CLICK for complete article
Nothing Goes to Hell in a Straight Line, not even on Wall Street.
I have to admit, it was the most volatile holiday period in the stock market and the credit markets that I can remember – and perhaps in history. All kinds of crazy things happened, just when market participation was thinnest. These were crazy moves. But those crazy moves won’t be the last crazy moves…. CLICK for complete article
On a historical basis, January is not as kind to U.S. equities as many investors believe it to be, but after a rough fourth quarter, the S&P 500 is starting 2019 on a strong note.
Following Monday’s gain, the benchmark U.S. equity gauge is up about 1.8 percent to start the new year…. CLICK for complete article